Preferred Label : Lerapolturev;
NCIt definition : A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral
poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced
with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity.
Upon administration of lerapolturev, the poliovirus is selectively taken up by and
replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually
causing tumor cell lysis. Following the lysis of infected cells, the replicated virus
is released and can infect adjacent cells, which both induces further tumor cell oncolysis
and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory
mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune
response. This further kills tumor cells. This may also stimulate long-term anti-tumor
immunity. Additionally, lerapolturev can induce a systemic anti-tumor immune response
through engagement with antigen-presenting cells (APCs) upon CD155 binding thereby
further killing tumor cells. CD155, an oncofetal cell adhesion molecule and tumor
antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme
(GMB), and plays an important role in tumor cell migration, invasion, and metastasis.
Due to the heterologous HRV2 IRES in this recombinant virus, lerapolturev only propagates
in susceptible CD155-expressing, nonneuronal neoplastic cells.;
UNII : MQ5GV2WUK4;
CAS number : 2430048-02-3;
Molecule name : PVS-RIPO;
NCI Metathesaurus CUI : CL1772885;
Origin ID : C184921;
UMLS CUI : C5669650;
Semantic type(s)
- Virus [UMLS semantic type]
- concept_is_in_subset
- has_target
